Prediction Case File
YouTubeTracking Live

Revealing My WORST Stock Investment of 2026!

1 extracted signal · 0 resolved · 1 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
20 Oct 2026, 18:30 UTC
Recorded by Tahlil Plus
20 Oct 2026, 21:39 UTC
Video preview for Revealing My WORST Stock Investment of 2026!
Source overview

AI-generated source summary

The video discusses SoFi Technologies (SOFI), highlighting its significant year-to-date decline of 48% and its current trading price of $14.30. The speaker notes personal experiences of buying SOFI at $14 in February and later at $8, resulting in a cost average below the current price, and mentions that the stock is currently up 120% for them from their lowest buy-in point. However, the analysis shifts to a more fundamental view. The speaker points out that while SoFi's share count has increased significantly, its tangible book value per share has more than doubled over the last four years, suggesting dilution has been less impactful than for some other companies. The company is identified as a lender, offering personal loans and student loans with strong average borrower income and FICO scores, indicating a decent quality customer base that can withstand economic weakness. The discussion also touches on SoFi's stablecoin initiative, SoFi USD, which is backed by reserves and offers a high interest rate. Despite the stock's historical performance and some fundamental strengths, the speaker highlights concerns about SoFi's innovation lagging behind competitors like Robinhood, which has been aggressively introducing new products and services. The valuation is also mentioned as being potentially too high previously, but now trading at a lower P/E ratio. The speaker's personal stance is to trim the position, not sell it entirely, and potentially add more if the stock becomes even more undervalued, while also expressing a preference for Robinhood due to its innovation.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
359
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail